of Panvax H1N1 Junior
THE Therapeutic Goods
Administration has advised that
stability testing of Panvax H1N1
Junior has revealed a decline in
potency of the product which is
supplied in 0.25ml pre-filled
syringes.
As such the TGA has advised CSL
that its 12 month shelf life
registration can no longer be
supported, and that the shelf life
has been reduced to six months.
As a result of this development
the TGA says that all existing
Panvax H1N1 Junior vaccine
0.25ml pre-filled syringe stores
should now be considered expired.
The decline in potency, according
to the TGA, seems to be linked to
the characteristics of the H1N1
virus itself.
The agency has however stressed
that the safety of the vaccine is not
affected.
Currently CSL is in the process of
retrieving all stock from
immunisation providers and
vaccination distribution points.
For more information see
www.tga.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.